Recent Transactions

Advised Pixelligent Technologies, a developer and manufacturer of nanocrystal material used in consumer electronic devices, on a significant strategic investment from Henkel Corporation, a publicly traded (FWB: HEN) German multinational chemical and consumer goods company

Advised Tanarra Capital, leading diversified alternative asset investment firm in Australia, on its sale of INX Software, leading end-to-end workforce management and EHS software provider for high-risk, complex and remote businesses, to Accel-KKR

Advised Liontown Resources on its strategic partnership and convertible note funding with LG Energy Solution

Advising Haleon plc on the sale of its global nicotine replacement therapy business (ex-US) to Dr. Reddy’s Laboratories

Advised U.S. Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on the refinancing of its senior secured notes

Advised Danone on its acquisition of Functional Formularies, a leading whole foods tube feeding business in the US, from Swander Pace Capital

Advising 1L Ad Hoc Group on the pre-packaged restructuring of Audacy, one of the largest multi-platform audio content and entertainment companies with 221 radio stations in 45 distinct markets

Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products

Advised Juice Plus+, a global health and wellness company in the direct selling space on a comprehensive recapitalization transaction

Sole financial adviser to Exponent, one of the UK’s leading private equity firms, on the acquisition of IFF’s Flavor Specialty Ingredients division, a global leader in the base aromas market

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies

Advising Eisai, a Japanese pharmaceutical company, on the sale of Eisai Distribution, a 100% shares holding logistic subsidiary, to Yasuda Logistics Corporation, a Japanese logistic company conducting total logistic services such as Warehousing, Transportation, delivery and forwarding, and Port transportation business, etc.